Cardiovascular Medtech Market Size, Share, Trends, Growth & Forecast 2034

Cardiovascular Medtech Industry Perspective:

The global cardiovascular MedTech market size was worth around USD 68.85 billion in 2024 and is predicted to grow to around USD 157.11 billion by 2034, with a compound annual growth rate (CAGR) of roughly 8.60% between 2025 and 2034.

Request Free Sample

Key Insights:

• As per the analysis shared by our research analyst, the global cardiovascular MedTech market is estimated to grow annually at a CAGR of around 8.60% over the forecast period (2025-2034)
• In terms of revenue, the global cardiovascular MedTech market size was valued at around USD 68.85 billion in 2024 and is projected to reach USD 157.11 billion by 2034.
• The cardiovascular MedTech market is projected to grow at a significant rate due to the growing number of patients with heart diseases.
• Based on the device type, the therapeutic & surgical devices segment is growing at a high rate and will continue to dominate the global market as per industry projections.
• Based on the application, the coronary artery disease segment is anticipated to command the largest market share.
• Based on region, North America is projected to dominate the global market during the forecast period.

Cardiovascular Medtech Market: Overview

Cardiovascular medical technology (MedTech) refers to the wide range of technological solutions and devices used for diagnosing, managing, and treating cardiovascular conditions. The sophisticated methods of managing heart-related conditions have proven more effective than traditional ways. The most common cardiovascular conditions reported worldwide include arrhythmia, heart valve disease, heart failure, peripheral artery disease, hypertension, coronary artery disease, stroke, and heart attack. The leading cardiovascular MedTech solutions witnessing higher revenue across the globe include next-generation imaging solutions, tools facilitating minimally invasive surgical procedures, and digital health solutions.

In the coming years, the adoption of digital twins technology in delivering solutions related to cardiovascular health is expected to emerge as a leading growth propeller for the industry players. During the forecast period, demand for cardiovascular MedTech is expected to grow due to the rising prevalence of heart conditions across the globe. Rising incidents of stroke and heart attack in children and young adults have become a major cause of concern among healthcare providers. However, the industry growth may be dampened due to the higher cost of the medical technology as well as limited adoption in emerging economies.

Cardiovascular Medtech Market: Market Dynamics

Growth Drivers

Will growing cases of patients with heart diseases drive the cardiovascular MedTech market demand rate?

The global cardiovascular MedTech market is expected to grow due to the rising prevalence of heart conditions across the globe. Cardiovascular diseases (CVDs) impact the heart and blood vessels. They can affect multiple parts of the blood vessels or the heart. If CVDs remain undiagnosed or untreated for an extended period, they can be life-threatening. According to the Cleveland Clinic, CVDs are the leading cause of medical deaths reported in the US. Some of the common symptoms of cardiovascular diseases include fainting, shortness of breath, chest pain, and exhaustion. The exact cause of CVDs depends on the type of heart condition. However, some of the leading risk factors include having a history of high cholesterol, high blood pressure, type 2 diabetes, tobacco consumption, excessive alcohol consumption, genetic cases of heart disease, and misuse of prescribed drugs.

In addition to this, recent trends indicate an increase in the number of younger CVD patients, including 9-year-old children. As per the Cardio Metabolic Institute, 1 in every 5 heart attack patients is below 40 years of age. It has become a global public health concern, resulting in greater use of CVD MedTech worldwide.

Rising sales of wearables are expected to promote market expansion in the long run

In recent times, wearables have gained significant growth momentum worldwide as a commonly used cardiovascular MedTech. Advanced wearables are equipped with next-generation sensor technology that monitors critical heart parameters such as heart rate, allowing early detection of an underlying condition. In May 2025, researchers at the University of Mississippi developed a new device that can detect a heart attack in real time.

According to the researchers, the device will ensure identification of a heart attack more accurately and rapidly than conventional methods. Rising health consciousness among the general population will promote higher use of wearables, further helping the global cardiovascular MedTech market thrive.

Restraints

High cost of advanced devices is expected to affect market revenue during the forecast period

The global cardiovascular MedTech industry is expected to be restricted due to the high expenses associated with the use of advanced devices. The average cost of an implantable pacemaker can range between USD 4200 and USD 10,000. On the other hand, leadless pacemakers can cost over USD 11,000. Furthermore, the overall expenses related to treatments integrating CVD MedTech may further put a financial burden on patients, especially those with a lack of access to medical insurance.

Opportunities

Growing research on the integration of digital twins technology opens new horizons for growth

The global cardiovascular MedTech market is expected to generate growth opportunities in the field of digital twins. The novel engineering solution deals with the use of computational models of biological systems and physical phenomena, facilitating the delivery of remote medicine. In May 2025, Imperial's National Heart and Lung Institute (NHLI), King's College London, along with the Alan Turing Institute, announced that they had developed around 3800 automatically correct digital hearts. The researchers are expected to use the digital twins for analyzing the impact of sex, heart, and other lifestyle factors on heart conditions. The researchers also established differences in electrocardiogram (ECG) readings between women and men using the digital twins.

How does rising focus on early detection of the underlying condition offer enhanced growth avenues for the cardiovascular MedTech industry?

Industry players are increasingly shifting their focus to early detection of heart conditions to prevent fatalities. Artificial Intelligence (AI) and Machine Learning (ML) are emerging as the leading technologies facilitating early diagnosis and prevention of CVDs. In February 2025, Heart Eye Diagnostics Limited, a UK-based MedTech firm, launched a new device for CVD risk assessment leveraging retinal scans. The device, called Dr. Noon, uses AI to detect and predict CVDs that may arise in the future. It is a non-invasive medical device based on advanced AI algorithms.

Challenges

Does the lack of access in emerging economies and insufficiently skilled professionals challenge the cardiovascular MedTech market expansion?

The global cardiovascular MedTech industry is expected to be challenged by the lack of access to the technologies in emerging economies. The healthcare industry continues to be dominated by traditional methods of CVD detection and management due to their widespread availability. Moreover, an insufficient number of skilled professionals with expertise in optimal management of new generational CVD MedTech may further impede market expansion in the coming years.

Cardiovascular Medtech Market: Report Scope

Cardiovascular Medtech Market: Segmentation

The global cardiovascular MedTech market is segmented based on device type, application, and region.

Based on the device type, the global market segments are therapeutic & surgical devices and diagnostic & monitoring devices. In 2024, the highest growth was listed in the therapeutic & surgical devices market, which dominated nearly 55% of the global revenue. It includes commonly used CVD treating technologies such as pacemakers and Transcatheter Aortic Valve Replacement (TAVR)-associated medical procedures. The common occurrence of cardiovascular diseases worldwide is expected to fuel segmental expansion in the future.

Based on the application, the global market is divided into valvular heart diseases, heart failure, coronary artery diseases, peripheral vascular diseases, and arrhythmia. In 2024, the highest revenue-generating segment was coronary artery disease, with control over 30.01% of the final revenue. Coronary artery disease is the leading cause of death due to heart-related ailments. It occurs when arteries supplying oxygen-containing blood to the heart become narrowed due to the collection of excessive fat or cholesterol.

Cardiovascular Medtech Market: Regional Analysis

What factors will help North America take the lead in the cardiovascular MedTech market during the forecast period?

The global cardiovascular MedTech market will be led by North America during the forecast period. The region will be dominated by the US in the coming years. North America has a robust healthcare infrastructure, with the majority of hospitals being equipped with next-generation medical technologies. In addition to this, cardiovascular diseases are widely prevalent across North America, especially in the US, driven by poor eating habits and greater consumption of processed food.

Furthermore, ongoing research & development in the regional CVD MedTech industry will further help North America thrive during the forecast period. In June 2024, AliveCor, a leading provider of AI-powered cardiology, announced that it had received US Food & Drug Administration (FDA) clearance for the Kardia™ 12L ECG System powered by KAI™ 12L AI technology. The tool is the world’s first AI-powered system capable of detecting life-threatening cardiac conditions such as heart attacks.

The North American market is heavily focusing on early detection and prevention of CVD, thus enabling greater investments in technologies that promote early diagnosis. In a recent event, Cardio Diagnostics Holdings Inc. from the US, launched PrecisionCHD. It is an integrated epigenetic-genetic blood test useful in detecting coronary heart disease in early stages.

Cardiovascular Medtech Market: Competitive Analysis

The global cardiovascular MedTech market is led by players like:

• GE HealthCare (GE Healthcare Technologies)
• Johnson & Johnson
• Abbott Laboratories
• Edwards Lifesciences
• LivaNova plc
• Cardinal Health
• Lepu Medical Technology (Beijing) Co. Ltd
• LeMaitre Vascular Inc
• Medtronic plc
• BIOTRONIK SE & Co. KG
• Boston Scientific Corporation
• OrbusNeich Medical Group Holdings
• Siemens Healthineers
• MicroPort Scientific Corporation
• B. Braun Melsungen AG

The global cardiovascular MedTech market is segmented as follows:

By Device Type

• Therapeutic & Surgical Devices
• Diagnostic & Monitoring Devices

By Application

• Valvular Heart Diseases
• Heart Failure
• Coronary Artery Diseases
• Peripheral Vascular Diseases
• Arrhythmia

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa